Moderna is gearing up for its next phase of growth, banking on its decade-long investment in messenger RNA (mRNA) technology to expand its medicines portfolio, strengthen commercial operations and build long-term revenue streams.

 

At its 2026 Analyst Day, Moderna laid out an ambitious growth strategy, highlighting the potential of its mRNA platform to deliver multiple classes of medicines and establish durable commercial franchises across infectious diseases, oncology and rare genetic disorders.

 

The company also outlined progress in its oncology pipeline, manufacturing capabilities and commercial expansion plans, while setting out its mid-term financial objectives.

 

"We founded Moderna on the belief that mRNA could transform medicine, and over the past decade we have built a powerful platform to realize that vision," said Stéphane Bancel, Chief Executive Officer of Moderna. 

 

"Our strategy is to create new modalities that can generate families of medicines and build durable franchises. We have demonstrated the potential of this approach in infectious diseases and are now advancing intismeran toward potential commercialization. Artificial intelligence and automation are accelerating what our platform can achieve, positioning Moderna to bring the next generation of mRNA medicines to patients around the world."

 

A major pillar of Moderna's growth strategy is its push beyond infectious disease vaccines into oncology and rare diseases.

 

The company has established three mRNA modalities covering infectious disease vaccines, individualized cancer treatments and rare genetic liver diseases. Its cancer candidate, intismeran, is moving closer to potential commercialisation following positive Phase 3 results in adjuvant melanoma, subject to regulatory approval.

 

Moderna is also looking to capitalise on several commercial opportunities from 2027 onwards, with an expanded respiratory vaccine portfolio and international market expansion expected to support growth.

 

Key growth drivers include:

 

Seasonal influenza: Following US and Canadian approvals of mFLUSIVA in 2026, Moderna is preparing for a broader commercial launch during the 2027-2028 respiratory season.

 

European expansion: With four approved respiratory vaccines in the European Union, the company is targeting further growth, particularly as a competitor COVID-19 vaccine contract expires.

 

Strategic partnerships: Long-term agreements in the UK, Canada and Australia are expected to generate recurring revenue while supporting domestic manufacturing. New agreements in Mexico and Taiwan are also opening doors to growth in Latin America and Asia-Pacific.

 

Expanded respiratory portfolio: Canada's approval of mCOFLU, Moderna's combination influenza and COVID-19 vaccine, known as mCOMBRIAX in the European Union, alongside European approval of mNEXSPIKE, adds further commercial opportunities.

 

Oncology expansion: Positive Phase 3 results for intismeran in adjuvant melanoma have strengthened the company's preparations for potential commercialisation, while Moderna continues to invest in additional cancer indications.

 

Artificial intelligence and automation are emerging as critical components of Moderna's next growth phase.

 

The company is integrating these technologies across its mRNA platform, linking computational design, laboratory experimentation and data analysis to accelerate scientific discovery and improve development efficiency.

 

Moderna is also applying AI and automation across manufacturing and business operations to boost productivity, streamline processes and strengthen capital efficiency.

 

Its broader strategy centres on leveraging shared technologies, delivery systems and manufacturing processes across multiple mRNA modalities. The approach is designed to reduce development costs, improve capital productivity and expand the range of potential applications for mRNA-based medicines.

 

Moderna said it plans to fund future investments in infectious disease vaccines through growth in its existing franchise, while directing balance sheet capital towards intismeran, cancer antigen therapies, rare diseases and emerging mRNA modalities.

 

Investment decisions will be driven by clinical evidence, commercial differentiation and the potential benefits to patients.

 

With its respiratory vaccine business providing an established commercial foundation, Moderna is increasingly looking to oncology and next-generation mRNA technologies to power its longer-term ambitions.

 

The company's message at Analyst Day was clear: the next chapter of growth will be built not just on vaccines, but on turning its mRNA platform into a broader engine for developing and commercialising medicines.